Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China flag China · Delayed Price · Currency is CNY
9.24
+0.05 (0.54%)
Oct 28, 2026, 3:04 PM CST

Yifan Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
311.21402.02385.97-551.07191.22278.4
Depreciation & Amortization
344.12344.12335.67270.6228.43207.18
Other Amortization
18.1618.169.939.219.486.88
Loss (Gain) From Sale of Assets
-12.7-12.7-30.15-2.570.56-14.83
Asset Writedown & Restructuring Costs
30.3730.3773.69872.46102.1338.25
Loss (Gain) From Sale of Investments
27.3127.3114.1615.0617.634.49
Provision & Write-off of Bad Debts
22.7522.7561.6360.4729.1221.34
Other Operating Activities
252.8854.5137-237.8938.4456.52
Change in Accounts Receivable
-109.04-109.04-363.72-10.25-103.77-18.59
Change in Inventory
-202.11-202.11-147.75-109.39-167.1-80.48
Change in Accounts Payable
-115.23-115.23239.9962.88156.63-99.34
Change in Other Net Operating Assets
18.0518.0519.7121.7923.15-10.3
Operating Cash Flow
565.93458.37640.73348.58472.07301.23
Operating Cash Flow Growth
-7.75%-28.46%83.81%-26.16%56.71%-72.82%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-593.27-559.23-628.16-504.09-542.27-571.74
Sale of Property, Plant & Equipment
30.1124.410.325.027.8417.7
Cash Acquisitions
1-----42
Divestitures
--5.291.061.215.9
Investment in Securities
-117.3180.5975-39.13-137.5866.6
Other Investing Activities
-26.960.132.674.30.655.64
Investing Cash Flow
-706.43-454.09-544.88-532.84-670.17-507.89

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-1,8572,0011,8551,7892,928
Long-Term Debt Repaid
--1,800-1,709-2,044-1,897-2,448
Lease Payments
-23.48-23.48-16.6-21.28-16.84-15.46
Net Debt Issued (Repaid)
447.3657.38291.87-189.38-107.72480.27
Issuance of Common Stock
----0.851
Repurchase of Common Stock
----38-53.56-121.47
Common Dividends Paid
-174.83-171.58-194.81-72.47-86.38-138.39
Other Financing Activities
-75.940.0315.67330.62234.150.75
Financing Cash Flow
196.59-114.17112.7330.78-12.66222.16

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-15.72-3.97-3.6914.5959.56-20.85
Net Cash Flow
40.37-113.87204.89-138.88-151.2-5.36

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-27.34-100.8712.57-155.5-70.21-270.51
Free Cash Flow Growth
------
Free Cash Flow Margin
-0.55%-1.97%0.24%-3.82%-1.83%-6.13%
Free Cash Flow Per Share
-0.02-0.080.01-0.13-0.06-0.22
Levered Free Cash Flow
16.87-56.25-194.48-168.05-347-430.33
Unlevered Free Cash Flow
47.9-23.1-151.29-120.83-293.35-383.71
Free Cash Flow After Leases
-50.83-124.35-4.03-176.78-87.05-285.96

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
314.23368.39321.69362.2291.5220.66
Change in Working Capital
-428.18-428.18-247.18-87.68-144.96-295.73